Abhinav Sidana, MD, MPH

Abhinav Sidana, MD, MPH, FACS

University of Chicago Medicine and Biological Sciences

Chicago, IL

Abhinav Sidana, MD, MPH, FACS, is an Associate Professor of Surgery, the Director of the Prostate Cancer Focal Therapy Program, the Co-Director of the High-Risk and Advanced Prostate Cancer Clinic, and a Urologic Oncologist at the University of Chicago in Illinois. Dr. Sidana specializes in prostate and kidney cancer, performing both robotic and open surgery for patients diagnosed with urologic cancers. He offers robotic prostatectomy for patients with more aggressive prostate cancer, and performs open and robotic surgery for patients with complex, multifocal, and advanced kidney cancers. Dr. Sidana’s research focuses on providing organ-preserving treatment, with lower side effects, for prostate cancer. He has extensive experience with cryoablation, high-intensity focused ultrasound ablation, TULSA Pro, and irreversible electroporation of the prostate.

Dr. Sidana earned his MBBS and MPH degrees from the All India Institute of Medical Sciences in New Delhi. He then completed a research fellowship in Urologic Cancers at the Brady Urological Institute of Johns Hopkins University in Baltimore, Maryland. Dr. Sidana then went on to complete a residency in Urology at the University of Cincinnati in Ohio, after which, he completed a fellowship in Urologic Oncology at the National Institutes of Health in Bethesda, Maryland.

Dr. Sidana is actively involved in urologic cancer research. He is investigating functional prostate imaging, image-guided and focal treatments for prostate cancer, as well as clinical trials on novel therapies for urologic cancers. Dr. Sidana has been the principal investigator of several interventional clinical trials in prostate cancer and has published over 100 peer-reviewed articles and book chapters. He also offers physician training and directs training courses for physicians in transperineal prostate biopsy techniques and focal therapy for prostate cancer.

Talks by Abhinav Sidana, MD, MPH, FACS

Whole Gland Ablation vs. Partial Gland Ablation

Abhinav Sidana, MD, MPH, FACS | Mar 2026

Dr. Abhinav Sidana contrasts whole gland and partial gland ablation, showing that partial ablation provides better potency. In contrast, whole gland ablation reduces the surveillance burden and may offer stronger oncologic assurance in selected men.

Genetic Testing in Prostate Cancer Management

Abhinav Sidana, MD, MPH, FACS | Mar 2026

A clear explanation of how germline and somatic testing guide treatment and risk assessment in prostate cancer care.

Panel Discussion: MRI and PSMA Discordance

Abhinav Sidana, MD, MPH, FACS, Steven P. Rowe, MD, PhD, Mark Emberton, MD, FRCS, Arvin K. George, MD and Sadhna M. Verma, MD, MBA, FSAR | Feb 2026

Experts discuss MRI and PSMA discordance, demonstrating how combined imaging enhances lesion evaluation.

Focal Therapy Recurrences and Management

Abhinav Sidana, MD, MPH, FACS | Jan 2026

Dr. Abhinav Sidana outlines recurrence detection and management in focal therapy for prostate cancer.

Mechanisms and Management of Recurrences

Abhinav Sidana, MD, MPH, FACS | Dec 2024

Abhinav Sidana, MD, MPH, delves into the mechanisms and management of recurrences in patients undergoing focal therapy. This 17-minute presentation underscores the absence of a consistent surveillance strategy and advocates for a standardized approach, combining PSA tests, MRI, and biopsies to detect clinically significant cancer.

Dr. Sidana identifies factors such as patient selection, multifocal disease, and tumor biology as primary contributors to failures. His talk also addresses the challenges of inadequate margins and the spatial localization of lesions. Management strategies for recurrences focus on returning to foundational clinical assessments, considering patient life expectancy, comorbidities, cancer grade, and preferences. Cases illustrating success and challenges in treatment strategies reinforce the need for individualized patient care.

Dr. Sidana advocates for integrating biopsies and MRIs into surveillance protocols and highlights patient selection as pivotal to reducing therapy failures. This comprehensive analysis aims to refine focal therapy practices and improve patient outcomes.